| Gene symbol | TNFRSF8 | Synonyms | CD30, D1S166E, Ki-1 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p36.22 | dbXrefs | |
| Description | TNF receptor superfamily member 8 | ||||
| GTO ID | GTC2986 |
| Trial ID | NCT05320081 |
| Disease | Lymphoma |
| Altered gene | CD30 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD30 CAR-T cells |
| Co-treatment | Camrelizumab |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma |
| Year | 2022 |
| Country | China |
| Company sponsor | Huazhong University of Science and Technology |
| Other ID(s) | MA-ML-Ⅱ-001 |
| Cohort 1 | |||||||||
|
|||||||||